Replies to post #254835 on Biotech Values

[DewDiligence]

Tang Capital acquires ELEV for $0.36/sh + CVR—an 18% premium to Friday’s close (excluding the CVR), but no premium ELEV’s net cash:

https://finance.yahoo.com/news/elevation-oncology-enters-agreement-acquired-120000586.html

The buyout price (excluding the CVR) is down 98% from ELEV’s 2021 IPO (#msg-164599586).